Maybe being bone-headed is a good thing.

With over 900,000 people getting diagnosed with Alzheimer’s every year in the US, scientists are on the hunt for new and better treatments. And it turns out some remedies could be right under our noses (and in our nightstands).

Yes: The beloved little blue pill, Viagra, has shown some promise sending blood to all the right places — like the brain, warding off dementia.

And now, new research shows a related drug that’s long been used for erectile dysfunction in Korea could soon help with Alzheimer’s in the US.

The drug, called AR1001, uses a lower dose of mirodenafil, an ED treatment used in Korea since 2007, to potentially treat Alzheimer’s.

A new clinical trial found it slowed cognitive decline by 31% — but only in a certain population.

AR1001’s maker AriBio plans to apply for FDA approval in 2027, meaning this new research could pave the way for the drug to land on the US market in the next few years.

Mirodenafil, sildenafil… and Alzheimer’s

Mirodenafil, the active ingredient in the new drug, and sildenafil, the active ingredient in Viagra, belong to the same class of drugs: PDE5 inhibitors.

These work by controlling breakdown of a chemical messenger called cGMP, keeping muscles relaxed and improving blood flow.

Normally, they’re prescribed to direct blood to the penis. But now, the drugs are being investigated for their ability to improve blood flow in the brain and improve cognitive function.

Blood flow plays a key part in Alzheimer’s development. Reduced blood flow allows toxic amyloid plaques to build up, and not enough oxygen and nutrients to supply brain cells.

What to know about AR1001

Unlike sildenafil, mirodenafil is not currently FDA approved for erectile dysfunction or any other use. But it has been approved in Korea for ED since 2007.

The latest research was part of its phase 3 clinical trials to investigate its safety and efficacy for Alzheimer’s treatment. It’s the last step before applying for FDA approval in the US.

After one year, patients taking AR1001 who were not on standard Alzheimer’s medications experienced 31% less clinical decline than those taking a placebo, according to the researchers.

However, when researchers looked at all 1,535 participants — including those taking other Alzheimer’s medications — the difference between AR1001 and placebo wasn’t statistically significant.

AR1001 users also generally saw better results on tests that measure memory, cognition and daily functioning, though not all results were statistically significant.

Researchers also found that AR1001 appeared to prevent the breakdown of a molecule that helps brain cells communicate, further evidence that the drug was having its intended effect.

Treating Alzheimer’s

There is no cure for Alzheimer’s, but there are treatments for symptoms and treatments that slow disease progression.

There are only two approved drugs right now to slow disease progression: Donanemab (Kisunla) and Lecanemab (Leqembi). Both are IV infusions and are made for early stage Alzheimer’s.

AR1001 would potentially join these two as approved medications to slow Alzheimer’s progression, but comes in the form of a once-a-day pill. It is also being studied for early stage Alzheimer’s only.

“We started developing AR1001 with the goal of creating an oral treatment that could slow Alzheimer’s progression and be practical for patients … to use over the long term,” said Jai-Jun Choung, CEO of AriBio.

The latest results “support our hypothesis,” he added. “Our vision is to broaden the treatment options available to patients and families.”

Share.